Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;259(3):852-61.
doi: 10.1148/radiol.11102023. Epub 2011 Apr 14.

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

David M Schuster  1 , Bital Savir-Baruch, Peter T Nieh, Viraj A Master, Raghuveer K Halkar, Peter J Rossi, Melinda M Lewis, Jonathon A Nye, Weiping Yu, F DuBois Bowman, Mark M Goodman
Affiliations

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

David M Schuster et al. Radiology. 2011 Jun.

Abstract

Purpose: To compare the diagnostic performance of the synthetic amino acid analog radiotracer anti-1-amino-3-fluorine 18-fluorocyclobutane-1-carboxylic acid (anti-3-(18)F-FACBC) with that of indium 111 ((111)In)-capromab pendetide in the detection of recurrent prostate carcinoma.

Materials and methods: This prospective study was approved by the institutional review board and complied with HIPAA guidelines. Written informed consent was obtained. Fifty patients (mean age, 68.3 years ± 8.1 [standard deviation]; age range, 50-90 years) were included in the study on the basis of the following criteria: (a) Recurrence of prostate carcinoma was suspected after definitive therapy for localized disease, (b) bone scans were negative, and (c) anti-3-(18)F-FACBC positron emission tomography (PET)/computed tomography (CT) and (111)In-capromab pendetide single photon emission computed tomography (SPECT)/CT were performed within 6 weeks of each other. Studies were evaluated by two experienced interpreters for abnormal uptake suspicious for recurrent disease in the prostate bed and extraprostatic locations. The reference standard was a combination of tissue correlation, imaging, laboratory, and clinical data. Diagnostic performance measures were calculated and tests of the statistical significance of differences determined by using the McNemar χ(2) test as well as approximate tests based on the difference between two proportions.

Results: For disease detection in the prostate bed, anti-3-(18)F-FACBC had a sensitivity of 89% (32 of 36 patients; 95% confidence interval [CI]: 74%, 97%), specificity of 67% (eight of 12 patients; 95% CI: 35%, 90%), and accuracy of 83% (40 of 48 patients; 95% CI: 70%, 93%). (111)In-capromab pendetide had a sensitivity of 69% (25 of 36 patients; 95% CI: 52%, 84%), specificity of 58% (seven of 12 patients; 95% CI: 28%, 85%), and accuracy of 67% (32 of 48 patients; 95% CI: 52%, 80%). In the detection of extraprostatic recurrence, anti-3-(18)F-FACBC had a sensitivity of 100% (10 of 10 patients; 95% CI: 69%, 100%), specificity of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 100% (17 of 17 patients; 95% CI: 80%, 100%). (111)In-capromab pendetide had a sensitivity of 10% (one of 10 patients; 95% CI: 0%, 45%), specificity of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 47% (eight of 17 patients; 95% CI: 23%, 72%).

Conclusion: anti-3-(18)F-FACBC PET/CT was more sensitive than (111)In-capromab pendetide SPECT/CT in the detection of recurrent prostate carcinoma and is highly accurate in the differentiation of prostatic from extraprostatic disease.

Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.11102023/-/DC1.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Flow diagram of study patients and results obtained for disease in the prostatic bed with 111In–capromab pendetide and anti-3-18F-FACBC.
Figure 2a:
Figure 2a:
Images in a patient who had undergone radical prostatectomy (PSA level, 16.9 ng/mL). (a) Sagittal PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Images were fused to same CT scan. Intense uptake between bladder base and rectum on scans obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to biopsy-proved recurrence. No uptake is seen in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide. Note bladder and rectal activity on 111In–capromab pendetide images (arrowheads in c and d).
Figure 2b:
Figure 2b:
Images in a patient who had undergone radical prostatectomy (PSA level, 16.9 ng/mL). (a) Sagittal PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Images were fused to same CT scan. Intense uptake between bladder base and rectum on scans obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to biopsy-proved recurrence. No uptake is seen in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide. Note bladder and rectal activity on 111In–capromab pendetide images (arrowheads in c and d).
Figure 2c:
Figure 2c:
Images in a patient who had undergone radical prostatectomy (PSA level, 16.9 ng/mL). (a) Sagittal PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Images were fused to same CT scan. Intense uptake between bladder base and rectum on scans obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to biopsy-proved recurrence. No uptake is seen in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide. Note bladder and rectal activity on 111In–capromab pendetide images (arrowheads in c and d).
Figure 2d:
Figure 2d:
Images in a patient who had undergone radical prostatectomy (PSA level, 16.9 ng/mL). (a) Sagittal PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Images were fused to same CT scan. Intense uptake between bladder base and rectum on scans obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to biopsy-proved recurrence. No uptake is seen in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide. Note bladder and rectal activity on 111In–capromab pendetide images (arrowheads in c and d).
Figure 3:
Figure 3:
Flow diagram of study patients and results obtained for extraprostatic disease with 111In–capromab pendetide and anti-3-18F-FACBC.
Figure 4a:
Figure 4a:
Images in a patient who had undergone radical prostatectomy (PSA level, 1.1 ng/mL). (a) Transverse PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Intense uptake on images obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to a 5-mm recurrence in the left obturator lymph node, which was proved at biopsy. There is no uptake in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide.
Figure 4b:
Figure 4b:
Images in a patient who had undergone radical prostatectomy (PSA level, 1.1 ng/mL). (a) Transverse PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Intense uptake on images obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to a 5-mm recurrence in the left obturator lymph node, which was proved at biopsy. There is no uptake in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide.
Figure 4c:
Figure 4c:
Images in a patient who had undergone radical prostatectomy (PSA level, 1.1 ng/mL). (a) Transverse PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Intense uptake on images obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to a 5-mm recurrence in the left obturator lymph node, which was proved at biopsy. There is no uptake in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide.
Figure 4d:
Figure 4d:
Images in a patient who had undergone radical prostatectomy (PSA level, 1.1 ng/mL). (a) Transverse PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Intense uptake on images obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to a 5-mm recurrence in the left obturator lymph node, which was proved at biopsy. There is no uptake in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide.
Figure 5a:
Figure 5a:
Images in a patient who had undergone radical prostatectomy (PSA level, 2.97 ng/mL). (a) Transverse PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Intense uptake on images obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to a subtle lytic bone lesion in the right pubic ramus, which was proved as recurrence at biopsy. There is no uptake in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide.
Figure 5b:
Figure 5b:
Images in a patient who had undergone radical prostatectomy (PSA level, 2.97 ng/mL). (a) Transverse PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Intense uptake on images obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to a subtle lytic bone lesion in the right pubic ramus, which was proved as recurrence at biopsy. There is no uptake in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide.
Figure 5c:
Figure 5c:
Images in a patient who had undergone radical prostatectomy (PSA level, 2.97 ng/mL). (a) Transverse PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Intense uptake on images obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to a subtle lytic bone lesion in the right pubic ramus, which was proved as recurrence at biopsy. There is no uptake in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide.
Figure 5d:
Figure 5d:
Images in a patient who had undergone radical prostatectomy (PSA level, 2.97 ng/mL). (a) Transverse PET and (b) fused PET/CT scans obtained with anti-3-18F-FACBC. (c) SPECT and (d) fused SPECT/CT scans obtained with 111In–capromab pendetide. Intense uptake on images obtained with anti-3-18F-FACBC (arrow in a and b) corresponded to a subtle lytic bone lesion in the right pubic ramus, which was proved as recurrence at biopsy. There is no uptake in same region on images obtained with 111In–capromab pendetide (arrow in c and d). This is an example of a true-positive finding with anti-3-18F-FACBC and a false-negative finding with 111In–capromab pendetide.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277–300 - PubMed
    1. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8(2):162–200 - PubMed
    1. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170(5):1872–1876 - PubMed
    1. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999;54(5):884–890 - PubMed
    1. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43(5):649–659 - PubMed

Publication types

MeSH terms